Alzheimer’s disease (AD) and vascular dementia (VaD) are the two most common types of dementia, and their incidence is increasing year by year. They affect the health of the elderly, and cause a huge burden on society, with no effective treatments currently available.
In vitro research is the first step in drug evaluation, and cellular immunofluorescence can be used to more clearly define the role of drugs, provide more comprehensive and accurate information for downstream drug development.
This study uses the Spark Cyto – an innovative multimode reader with cell imaging capabilities – to evaluate the neuroprotective effects of miR-23b-3p (miRNA) and tilianin (compound) on stable transfected cell lines and human primary neurons. The results in this application note are based on a peer-reviewed article, published in the journal Oxidative Medicine and Cellular Longevity in August,2021, with the title: Tilianin Ameliorates Cognitive Dysfunction and Neuronal Damage in Rats with Vascular Dementia via p-CaMKII/ERK/CREB and ox-CaMKII-Dependent MAPK/NF-κB Pathways.